Citations

Clear

2 citation(s) found for "Shrestha, Roshan".

SARC031: A Phase II Trial of Selumetinib and Sirolimus for Patients with Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors (MPNST)
Kim, Aerang, Ballman, K., Wolters, Pamela L. , Heise, Rachel S. , Shern, J., Sundby, R. Taylor , Lindenberg, Liza , Lee, Min-Jung , Rastogi, Shraddha , Shahsavari, Shirin, Tine, Brian A. Van, Meyer, Christian F. , Pratilas, Christine A. , Collins, Natalie B. , Coyne, Geraldine O'Sullivan, Chen, Alice P. , Dombi, Eva, Shrestha, Roshan L., Cichowski, Karen M. , Widemann, B. C., Ballman, Karla V. , Kim, AeRang , Cichowski, Karen , Shern, Jack F. , Sundby, R. Taylor , Kim, AeRang , Ballman, Karla , Shern, Jack F , Sato, Nahoko , Shahsavari, Shirin , Hirbe, Angela C , Van Tine, Brian A , Meyer, Christian , Pratilas, Christine A , Collins, Natalie B , O'Sullivan Coyne, Geraldine , Chen, Alice P , Dombi, Eva , Shrestha, Roshan L , Gross, Andrea M , Reinke, Denise , Widemann, Brigitte C , Heise, Rachel , Wolters, Pamela L. , Hirbe, Angela C. , Tine, Brian A. Van , Dombi, Eva , Gross, Andrea M. , Reinke, Denise K.

Mayo Clinic

Clinical Cancer Research | January 8, 2026 | Volume: 32 | Issue: 6 | Pages: 1068-1077

10.1158/1078-0432.ccr-25-2887 | PMID 41504652 Get It

Abstract Purpose: Combined mTOR and MEK inhibition, critical components of the RAS effector pathway underlying the pathogenesis of neurofibromatosis type 1 (NF1)–related tumors, caused regression in a malignant peripheral nerve sheath tumor (MPNST) transgenic mouse model. The primary objective was to determine the clinical benefit rate in patients with unresectable/metastatic MPNST. Patients and Methods: The study design was a multi-institutional, open-label, Simon two-stage, phase II study of the MEK inhibitor selumetinib and mTOR inhibitor sirolimus. Patients ≥12 years with histologically confirmed MPNST received selumetinib 50 mg twice daily and sirolimus 4 mg once daily, in continuous 28-day cycles. Correlative studies evaluated patient-reported pain, immune signature in peripheral blood, and cell-free DNA (cfDNA). Results: A total of 21 heavily pretreated patients [seven females; median age, 41 years (range, 16–72); and 14 with NF1] with advanced disease enrolled at five participating sites. Clinical benefit was observed in only one of seven in stage 1 and one of 14 patients in stage 2. The median number of cycles was two (range, 1–6). Most common adverse events (AE) were grade ≤2 gastrointestinal toxicity, acneiform rash, hypertriglyceridemia, mucositis, and transaminase elevation. Unlike the preclinical model, early 18F-fluorodeoxyglucose PET scan performed during cycle 1 demonstrated partial metabolic responses in five patients (24%), but these did not correlate with objective responses after cycle 2. cfDNA was able to detect MPNST with the potential to be a biomarker of response. Conclusions: The combination was safe, with manageable and expected AEs, but did not meet study parameters for further evaluation in MPNST. Correlative studies were informative and may guide future therapeutic trials of MPNST.
Treating Philadelphia chromosome/BCR‐ABL1 positive patients with Glivec (Imatinib mesylate): 10 years’ experience at Patan Hospital, Nepal
Kayastha, Gyan , Ranjitkar, Nora, Gurung, Radha, KC, Raj Kumar, Karki, Sanjit , Shrestha, Roshan , Thapa, Raj Kumar , Rajbhandari, Piyush , Poudyal, Buddhi, Acharya, Paras Kumar , Hayes, Bruce , Zimmerman, Mark, Mansfield, Aaron S. , Basnyat, Buddha , Mansfield, Aaron, Roberts, David J. , Mansfield, Aaron S

Mayo Clinic

British Journal of Haematology | March 29, 2017 | Volume: 177 | Issue: 6 | Pages: 991-999

10.1111/bjh.14645 | PMID 28369812 Get It

SummaryThe Glivec International Patient Assistance Programme makes Glivec (Imatinib mesylate) available to Philadelphia chromosome/BCR‐ABL1 positive patients with chronic myeloid leukaemia (CML) in Lower and Middle Income Countries (LMIC). We have established a large cohort of 211 CML patients who are eligible for Imatinib, in Kathmandu, Nepal. Thirty‐one patients were lost to follow‐up. We report on 180 CML patients with a median age of 38 years (range 9–81). Of these 180 patients, 162 underwent cytogenetic testing and 110 were investigated by reverse transcription polymerase chain reaction. One hundred and thirty‐nine of the 180 patients (77·2%) had at least one optimal response. Taken together, our cohort has a 95% overall survival rate and 78% of the patients were still taking Glivec at a median time of 48·8 months (range 3–140 months). The number of patients who actually failed therapy, as defined by the LeukaemiaNet 2013 criteria, was 39 (21·7%). While our cohort has some differences with those in North America or Europe, we have shown Glivec is effective in inducing an optimal response in our patients in Nepal and that it is possible to deliver a clinical service for CML patients using tyrosine kinase inhibitors in resource‐poor settings.